FAM148C inhibitors are a class of compounds that indirectly influence the activity of the FAM148C protein by targeting signaling pathways and cellular processes that FAM148C is speculated to interact with or be regulated by. The primary mechanisms through which these inhibitors operate involve the interruption of kinase signaling cascades which are crucial for multiple cellular functions, including growth, proliferation, and survival.
Rapamycin and its analogs (such as PP242, Torin 1, and AZD8055) specifically target the mTOR pathway, which is integral to cell growth and metabolism. By inhibiting mTORC1 and potentially mTORC2, these compounds may affect the activity of proteins that are regulated by these complexes, potentially including FAM148C. LY294002 and Wortmannin are both PI3K inhibitors. The PI3K/AKT/mTOR pathway is a critical signaling pathway that regulates cell survival and proliferation. By inhibiting PI3K, these compounds can lead to reduced activation of AKT and subsequent mTORC1 signaling, which in turn could impact proteins that are downstream or related to this pathway, such as FAM148C.